pharma
Novartis’ Mayzent delays time wheelchair dependence by 4 years in secondary progressive multiple sclerosis
September 12, 2019Research and Development ECTRIMS 2019, Mayzent, Novartis, multiple sclerosis, pharma
Novartis has taken the opportunity at the 2019 Congress of The European Committee for Treatment and Research in Multiple Sclerosis …
Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis
September 11, 2019Research and Development Biogen, multiple sclerosis, pharma, tecfidera
Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period …
BMS unveils strong five-year efficacy data for Opdivo in lung cancer
September 11, 2019Research and Development Bristol-Myers Squibb, Cancer, immunotherapy, lung cancer, pharma
Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase …
Tony Coles appointed to Pfizer Spinout Cerevel as CEO
September 10, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cerevel, Pfizer, pharma
Cerevel Therapeutics, a pharmaceutical company dedicated to treating neurological diseases, has appointed renowned biotechnology leader Tony Coles as Chief Executive …
MSD’s Keytruda approved for first-line lung cancer use on NHS Scotland
September 10, 2019Manufacturing and Production, Sales and Marketing Cancer, MSD, SMC, Scotland, keytruda, lung cancer, pharma
MSD and lung cancer patients will be celebrating the news that the pharma giant’s immunotherapy Keytruda (pembrolizumab) has been accepted …
Boehringer’s Ofev scores first-of-its-kind FDA approval in rare lung disease
September 10, 2019Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, FDA, US, lungs, ofev, pharma, rare disease
Boehringer Ingelheim’s Ofev (nintedanib) capsules have now secured marketing authorisation in the US, it has emerged, for the treatment of …
Lilly’s LOXO-292 shrinks tumours in lung cancer trial
September 9, 2019Research and Development, Sales and Marketing Cancer, Eli Lilly, lung cancer, pharma
Eli Lilly has announced its experimental cancer drug LOXO-292, acquired in January, shrank tumours in almost 70% of advanced lung …
Age affects efficacy of immunotherapy treatments in breast cancer patients
September 9, 2019Research and Development, Sales and Marketing Cancer, breast cancer, pharma
Recent clinical trial data has shown that immune checkpoints blockade (ICB) therapy, designed to unleash a patient’s immune system to …
Trump’s FDA: Is the US regulator being steered by the President?
September 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Trump, US, drug safety, pharma
FDA activity has fallen under Donald Trump, with the number of warning letters issued by the regulator dropping by a …
4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine
September 9, 2019Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma
Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …
AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer
September 9, 2019Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …
Roche celebrates European approval of Tecentriq combo in first-line lung cancer
September 6, 2019Medical Communications, Sales and Marketing Cancer, Europe, Roche, lung cancer, pharma, tecentriq
Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) …
Novartis’ Lucentis secures European approval for infants with rare eye disease
September 6, 2019Medical Communications, Sales and Marketing Europe, Lucentis, Novartis, eye disease, pharma
Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the European …
Experimental Novartis drug secures FDA Breathrough designation for rare lung cancer
September 6, 2019Medical Communications, Sales and Marketing Cancer, Novartis, capmatinib, lung cancer, pharma
Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing …
View of pharma industry sinks to new low in US, poll reveals
September 6, 2019Medical Communications US, pharma
The public have always been reticent with their trust in the pharmaceutical industry, but that trust has hit an all-time …
Latest content
Five Facts about cardiovascular disease
